

State of Misconsin 2013 - 2014 LEGISLATURE



2013 ASSEMBLY BILL 406

October 4, 2013 – Introduced by Representatives BIES, BEWLEY, MILROY, BALLWEG, BERCEAU, BERNIER, BROOKS, CZAJA, GOYKE, JACQUE, KNUDSON, KOLSTE, T. LARSON, OHNSTAD, A. OTT, RINGHAND, SPIROS, TITTL, WACHS and BERNARD SCHABER, cosponsored by Senators HARSDORF, JAUCH, KEDZIE, GUDEX and LASSA. Referred to Committee on Criminal Justice.

1	$AN \ ACT \ \textit{to repeal} \ 941.318, \ 961.14 \ (4) \ (te), \ (th), \ (tL), \ (tp), \ (tr), \ (tu) \ and \ (ty) \ and \ (ty) \ (tr), \ (tu) \ (tu) \ (tr), \ (tu) \ (t$
2	961.14 (7) (m) and (n); to amend 59.54 (25g), 66.0107 (1) (bn), 961.14 (4)
3	(intro.), 961.14 (7) (intro.), 961.41 (1) (e) (intro.), 961.41 (1) (hm) (intro.), 961.41
4	(1m) (e) (intro.), 961.41 (1m) (hm) (intro.), 961.41 (1r), 961.41 (3g) (d) and 961.41 (d)
5	(3g) (em); to repeal and recreate 961.14 (4) (tb) and 961.14 (7) (L); and to
6	<i>create</i> 961.14 (4) (sm), 961.14 (4) (uv), 961.14 (4) (wa), 961.14 (4) (wb), 961.14
7	$(4) \ (wk), \ 961.14 \ (4) \ (wL), \ 961.14 \ (4) \ (wm), \ 961.14 \ (4) \ (wn), \ 961.14 \ (4) \ (wo), \ 961.14 \ (4) $
8	$(4) \ (wp), \ 961.14 \ (4) \ (wq), \ 961.14 \ (4) \ (wr), \ 961.14 \ (4) \ (ws), \ 961.14 \ (4) \ (wv), \ 961.14 \ (4) \ ($
9	(4) (ww), 961.14 (4) (wx), 961.14 (4) (wy), 961.14 (4) (wz), 961.14 (4) (xa), 961.14 (xa), 961
10	$(4) \ (xb), \ 961.14 \ (7) \ (mk), \ 961.14 \ (7) \ (mL), \ 961.14 \ (7) \ (mm), \ 961.14 \ (7) \ (mn), \ 961.14 \ (7) \ ($
11	961.16 (3) (tb), 961.16 (3) (zt), 961.16 (8) (b), 961.18 (7) (am), 961.18 (7) (az),
12	961.18 (7) (em), 961.20 (2) (ax), 961.20 (2) (q), 961.20 (4) (d), 961.22 (4), 961.22

1

(5), 961.41 (1) (em) and 961.41 (1m) (em) of the statutes; **relating to:** controlled

 $\mathbf{2}$

substances, and providing a penalty.

Analysis by the Legislative Reference Bureau

Under current law, controlled substances are classified in one of five separate schedules. The classification is based on: 1) whether there is a currently accepted medical use for the drug; 2) the drug's potential for being abused; and 3) the nature of the psychological or physical dependence that the drug use may produce.

Schedule I controlled substances are those that have a high potential for abuse and no currently accepted medical use. Schedule V controlled substances are those that have an accepted medical use and that have a lower potential for abuse and produce less dependence when compared with other controlled substances. Penalties for crimes relating to Schedule I controlled substances are generally the most severe, and for Schedule V controlled substances are generally the least severe.

Under current law, eight synthetic cannabinoids and two stimulant substances commonly known as "bath salts" are classified as Schedule I controlled substances. Current law also penalizes the possession, manufacture, delivery, or distribution of the analogs of these substances. Current law defines a controlled substance analog as a substance that has a chemical structure substantially similar to the chemical structure of a controlled substance in Schedule I or II, and that has a similar effect on the user of the substance as the controlled substance.

Current law also penalizes the manufacture, distribution, or delivery of Salvinorin A, a psychotropic ingredient in the plant *Salvia divinorum*, but does not classify that substance as a controlled substance.

Under this bill, the concept of an analog of a synthetic cannabinoid or of a bath salt stimulant is replaced with a description of the chemical structure of the prohibited or restricted substance. The bill controls synthetic cannabinoids, certain other designer drugs, and certain substances known as bath salts as part of distinct structural classes. Under the bill, any substance, listed or not, that conforms to the structural definition is controlled by the particular structural class. The bill adds several new hallucinogenic and stimulant substances to Schedule I, and includes Salvinorin A in the list of Schedule I controlled substances.

The bill also adds several new Schedule II, III, IV, and V controlled substances by including in those schedules a description of the chemical structure of those substances.

Because this bill creates a new crime or revises a penalty for an existing crime, the Joint Review Committee on Criminal Penalties may be requested to prepare a report concerning the proposed penalty and the costs or savings that are likely to result if the bill is enacted.

For further information see the *state and local* fiscal estimate, which will be printed as an appendix to this bill.

The people of the state of Wisconsin, represented in senate and assembly, do enact as follows:

1	SECTION 1. 59.54 (25g) of the statutes is amended to read:
2	59.54 (25g) Possession of a synthetic cannabinoid. The board may enact and
3	enforce an ordinance to prohibit the possession of any controlled substance specified
4	in s. 961.14 (4) (tb) to (ty), and provide a forfeiture for a violation of the ordinance,
5	except that any person who is charged with possession of a controlled substance
6	specified in s. 961.14 (4) (tb) to (ty) following a conviction for possession of a controlled
7	substance in this state shall not be prosecuted under this subsection. Any ordinance
8	enacted under this subsection applies in every municipality within the county.
9	SECTION 2. 66.0107 (1) (bn) of the statutes is amended to read:
10	66.0107 (1) (bn) Enact and enforce an ordinance to prohibit the possession of
11	a controlled substance specified in s. 961.14 (4) (tb) to (ty) and provide a forfeiture
12	for a violation of the ordinance, except that any person who is charged with
13	possession of a controlled substance specified in s. 961.14 (4) (tb) to (ty) following a
14	conviction for possession of a controlled substance in this state shall not be
15	prosecuted under this paragraph.
16	SECTION 3. 941.318 of the statutes is repealed.
17	SECTION 4. 961.14 (4) (intro.) of the statutes is amended to read:
18	961.14 (4) HALLUCINOGENIC SUBSTANCES. (intro.) Any material, compound,

961.14 (4) HALLUCINOGENIC SUBSTANCES. (intro.) Any material, compound,
 mixture or preparation which contains any quantity of any of the following
 hallucinogenic substances, including any of their salts, isomers, precursors, analogs,
 esters, ethers, and salts of isomers, esters, or ethers that are theoretically possible

ASSEMBLY BILL 406

within the specific chemical designation, in any form contained in a plant, obtained
 from a plant, or chemically synthesized:

- **SECTION 5.** 961.14 (4) (sm) of the statutes is created to read:
- 4 961.14 (4) (sm) Salvinorin A;

SECTION 6. 961.14 (4) (tb) of the statutes is repealed and recreated to read:

6 961.14 (4) (tb) Synthetic cannabinoids, including:

- 7 Any compound structurally derived from 3-(1-naphthoyl)indole or 1. 1H-indol-3-yl-(1-naphthyl)methane by substitution at the nitrogen atom of the 8 9 indole ring by alkyl, haloalkyl, cyanoalkyl, alkenyl, cycloalkylmethyl, 10 1-(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, cycloalkylethyl, 11 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or (tetrahydropyran-4-yl)methyl group, whether or not further substituted in the 1213indole ring to any extent, whether or not substituted in the naphthyl ring to any 14extent. Substances specified under this subdivision include:
- a. 1-pentyl-2-methyl-3-(1-naphthoyl)indole, commonly known as
 JWH-007;
- b. 1-propyl-2-methyl-3-(1-naphthoyl)indole, commonly known as
 JWH-015;
- c. 1-pentyl-3-(1-naphthoyl)indole, commonly known as JWH-018 or
 AM-678;

d. 1-hexyl-3-(1-naphthoyl)indole, commonly known as JWH-019;

e. 1-butyl-3-(1-naphthoyl)indole, commonly known as JWH-073;

f. 1-pentyl-3-(4-methoxy-1-naphthoyl)indole, commonly known as
JWH-081;

- 4 -

ASSEMBLY BILL 406

1	g. 1-pentyl-2-methyl-3-(4-methoxy-1-naphthoyl)indole, commonly known
2	as JWH-098;
3	h. 1-pentyl-3-(4-methyl-1-naphthoyl)indole, commonly known as
4	JWH-122;
5	i. 1-pentyl-3-(7-methoxy-1-naphthoyl)indole, commonly known as
6	JWH-164;
7	j. 1-[2-(4-(morpholinyl)ethyl)]-3-(1-naphthoyl)indole, commonly known as
8	JWH-200;
9	k. 1-pentyl-3-(4-ethyl-1-naphthoyl)indole, commonly known as JWH-210;
10	L. 1-pentyl-3-(4-chloro-1-naphthoyl)indole, commonly known as JWH-398;
11	m. 1-pentyl-3-(4-fluoro-1-naphthoyl)indole, commonly known as JWH-412;
12	$n. \ 1-[1-(N-methyl-2-piperidinyl)methyl]-3-(1-naphthoyl)indole, \ commonly \ not $
13	known as AM–1220;
14	o. 1-(5-fluoropentyl)-3-(1-naphthoyl)indole, commonly known as AM-2201;
15	p. $1-(5-fluoropentyl)-3-(4-methyl-1-naphthoyl)$ indole, commonly known as
16	MAM-2201;
17	q. 1-(5-chloropentyl)-3-(1-naphthoyl)indole, commonly known as AM-2201
18	(5-chloropentyl);
19	r. 1-(5-bromopentyl)-3-(1-naphthoyl)indole, commonly known as AM-2201
20	(5-bromopentyl);
21	s. 1-(4-cyanobutyl)-3-(1-naphthoyl)indole, commonly known as AM-2232;
22	t.
23	(R)-(+)-[2,3-dihydro-5-methyl-3-(4-morpholinylmethyl)pyrrolo[1,2,3-de]-1,4-b](R)-(+)-[2,3-dihydro-5-methyl-3-(4-morpholinylmethyl)pyrrolo[1,2,3-de]-1,4-b](R)-(4-morpholinylmethyl-1,4-b](R)-(4-morpholinylmethyl-1,4-b](R)-(4-morpholinylmethyl-1,4-b](R)-(4-morpholinylmethyl-1,4-b](R)-(4-morpholinylmethyl-1,4-b](R)-(4-morpholinylmethyl-1,4-b](R)-(4-morpholinylmethyl-1,4-b](R)-(4-morpholinylmethyl-1,4-b](R)-(4-morpholinylmethyl-1,4-b](R)-(4-morpholinylmethyl-1,4-b](R)-(4-morpholinylmethyl-1,4-b](R)-(4-morpholinylmethyl-1,4-b](R)-(4-morpholinylmethyl-1,4-b](R)-(4-morpholinylmethyl-1,4-b](R)-(4-morpholinylmethyl-1,4-b](R)-
24	enzoxazin-6-yl]-1-naphthalenyl-methanone, commonly known as WIN 55,212-2;

- 5 -

ASSEMBLY BILL 406

1	2. Any compound structurally derived from 3-(1-naphthoyl)pyrrole by
2	substitution at the nitrogen atom of the pyrrole ring by alkyl, haloalkyl, cyanoalkyl,
3	$alkenyl,\ cycloalkylmethyl,\ cycloalkylethyl,\ 1-(N-methyl-2-piperidinyl)methyl,$
4	2-(4-morpholinyl)ethyl, 1-(N-methyl-2-pyrrolidinyl)methyl,
5	$1-(N-methyl-3-morpholinyl) methyl, \ or \ (tetrahydropyran-4-yl) methyl \ group,$
6	whether or not further substituted in the pyrrole ring to any extent, whether or not
7	substituted in the naphthyl ring to any extent. Substances specified under this
8	subdivision include:
9	a. 1-pentyl-5-(2-fluorophenyl)-3-(1-naphthoyl)pyrrole, commonly known as
10	JWH-307;
11	b. 1-pentyl-5-(2-methylphenyl)-3-(1-naphthoyl)pyrrole, commonly known
19	as JWH-370;
12	
12	c. 1-pentyl-3-(1-naphthoyl)pyrrole, commonly known as JWH-030;
13	c. 1-pentyl-3-(1-naphthoyl)pyrrole, commonly known as JWH-030;
13 14	c. 1-pentyl-3-(1-naphthoyl)pyrrole, commonly known as JWH-030; d. 1-hexyl-5-phenyl-3-(1-naphthoyl)pyrrole, commonly known as JWH-147;
13 14 15	 c. 1-pentyl-3-(1-naphthoyl)pyrrole, commonly known as JWH-030; d. 1-hexyl-5-phenyl-3-(1-naphthoyl)pyrrole, commonly known as JWH-147; 3. Any compound structurally derived from 3-naphthylmethylindene by
13 14 15 16	 c. 1-pentyl-3-(1-naphthoyl)pyrrole, commonly known as JWH-030; d. 1-hexyl-5-phenyl-3-(1-naphthoyl)pyrrole, commonly known as JWH-147; 3. Any compound structurally derived from 3-naphthylmethylindene by substitution at the 1-position of the indene ring by alkyl, haloalkyl, cyanoalkyl,
13 14 15 16 17	 c. 1-pentyl-3-(1-naphthoyl)pyrrole, commonly known as JWH-030; d. 1-hexyl-5-phenyl-3-(1-naphthoyl)pyrrole, commonly known as JWH-147; 3. Any compound structurally derived from 3-naphthylmethylindene by substitution at the 1-position of the indene ring by alkyl, haloalkyl, cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl,
13 14 15 16 17 18	 c. 1-pentyl-3-(1-naphthoyl)pyrrole, commonly known as JWH-030; d. 1-hexyl-5-phenyl-3-(1-naphthoyl)pyrrole, commonly known as JWH-147; 3. Any compound structurally derived from 3-naphthylmethylindene by substitution at the 1-position of the indene ring by alkyl, haloalkyl, cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1-(N-methyl-2-pyrrolidinyl)methyl,
13 14 15 16 17 18 19	 c. 1-pentyl-3-(1-naphthoyl)pyrrole, commonly known as JWH-030; d. 1-hexyl-5-phenyl-3-(1-naphthoyl)pyrrole, commonly known as JWH-147; 3. Any compound structurally derived from 3-naphthylmethylindene by substitution at the 1-position of the indene ring by alkyl, haloalkyl, cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or (tetrahydropyran-4-yl)methyl group,
13 14 15 16 17 18 19 20	 c. 1-pentyl-3-(1-naphthoyl)pyrrole, commonly known as JWH-030; d. 1-hexyl-5-phenyl-3-(1-naphthoyl)pyrrole, commonly known as JWH-147; 3. Any compound structurally derived from 3-naphthylmethylindene by substitution at the 1-position of the indene ring by alkyl, haloalkyl, cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or (tetrahydropyran-4-yl)methyl group, whether or not further substituted in the indene ring to any extent, whether or not
13 14 15 16 17 18 19 20 21	 c. 1-pentyl-3-(1-naphthoyl)pyrrole, commonly known as JWH-030; d. 1-hexyl-5-phenyl-3-(1-naphthoyl)pyrrole, commonly known as JWH-147; 3. Any compound structurally derived from 3-naphthylmethylindene by substitution at the 1-position of the indene ring by alkyl, haloalkyl, cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or (tetrahydropyran-4-yl)methyl group, whether or not further substituted in the indene ring to any extent, whether or not substituted in the naphthyl ring to any extent. Substances specified under this

4. Any compound structurally derived from 3-phenylacetylindole by
substitution at the nitrogen atom of the indole ring with alkyl, haloalkyl, cyanoalkyl,

- 6 -

ASSEMBLY BILL 406

1	alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl,
2	2-(4-morpholinyl)ethyl, 1-(N-methyl-2-pyrrolidinyl)methyl,
3	1-(N-methyl-3-morpholinyl) methyl, or (tetrahydropyran-4-yl) methyl group,
4	whether or not further substituted in the indole ring to any extent, whether or not
5	substituted in the phenyl ring to any extent. Substances specified under this
6	subdivision include:
7	a. 1-pentyl-3-(4-methoxyphenylacetyl)indole, commonly known as
8	JWH-201;
9	b. 1-pentyl-3-(3-methoxyphenylacetyl)indole, commonly known as
10	JWH-302;
11	c. 1-pentyl-3-(2-methoxyphenylacetyl)indole, commonly known as
12	JWH-250;
13	d. 1-pentyl-3-(2-chlorophenylacetyl)indole, commonly known as JWH-203;
14	e. 1-pentyl-3-(3-chlorophenylacetyl)indole, or 3-chloro isomer of JWH-203;
15	f. 1-pentyl-3-(4-chlorophenylacetyl)indole, or 4-chloro isomer of JWH-203;
16	g. 1-pentyl-3-(2-methylphenylacetyl)indole, commonly known as JWH-251;
17	$h. \qquad 1-(2-cyclohexylethyl)-3-(2-methoxyphenylacetyl) indole, commonly$
18	known as RCS-8;
19	$i. \ 1-[1-(N-methyl-2-piperidinyl)methyl]-3-(2-methoxyphenylacetyl) indole,$
20	commonly known as cannabipiperidiethanone;
21	5. Any compound structurally derived from 2-(3-hydroxycyclohexyl)phenol by
22	substitution at the 5-position of the phenolic ring by alkyl, haloalkyl, cyanoalkyl,
23	$alkenyl,\ cycloalkylmethyl,\ cycloalkylethyl,\ 1-(N-methyl-2-piperidinyl)methyl,$
24	$2-(4-morpholinyl) ethyl, \\ 1-(N-methyl-2-pyrrolidinyl) methyl,$
25	$1-(N-methyl-3-morpholinyl) methyl, \ or \ (tetrahydropyran-4-yl) methyl \ group,$

ASSEMBLY BILL 406

1	whether or not substituted in the cyclohexyl ring to any extent. Substances specified
2	under this subdivision include:
3	a. $2-[(1R,3S)-3-hydroxycyclohexyl]-5-(2-methyloctan-2-yl)phenol,$
4	commonly known as CP 47,497;
5	$b. \qquad 2-[(1R,3S)-3-hydroxycyclohexyl]-5-(2-methylnonan-2-yl)phenol, \\$
6	commonly known as CP 47,497 C8 homologue, or cannabicyclohexanol;
7	6. Any compound structurally derived from 3–(benzoyl)indole by substitution
8	at the nitrogen atom of the indole ring by alkyl, haloalkyl, cyanoalkyl, alkenyl,
9	$\label{eq:cycloalkylmethyl} cycloalkylmethyl, \qquad cycloalkylethyl, \qquad 1-(N-methyl-2-piperidinyl)methyl,$
10	2-(4-morpholinyl)ethyl, 1-(N-methyl-2-pyrrolidinyl)methyl,
11	1-(N-methyl-3-morpholinyl) methyl, or (tetrahydropyran-4-yl) methyl group, (tetrahydropyran-4-yl) methyl (tetrahydr
12	whether or not further substituted in the indole ring to any extent and whether or
13	not substituted in the phenyl ring to any extent. Substances specified under this
14	subdivision include:
15	a. 1-pentyl-3-(2-iodobenzoyl)indole, commonly known as AM-679;
16	b. 1–(5–fluoropentyl)–3–(2–iodobenzoyl)indole, commonly known as AM–694;
17	c. 1-pentyl-3-(4-methoxybenzoyl)indole, commonly known as RCS-4;
18	d. 1-butyl-3-(4-methoxybenzoyl)indole, commonly known as RCS-4-C4
19	homologue;
20	e. 1-pentyl-3-(2-methoxybenzoyl)indole, commonly known as RCS-4
21	2-methoxy isomer;
22	f. 1-butyl-3-(2-methoxybenzoyl)indole, a C4 homologue, 2-methoxy isomer
23	of RCS-4;
24	$g. \qquad 1-[2-(4-(morpholinyl)ethyl]-2-methyl-3-(4-methoxybenzoyl)indole, and a second s$
25	commonly known as pravadoline, or WIN 48,098;

- 8 -

1	h.
	1-[2-(4-(morpholinyl)ethyl]-2-methyl-3-(4-methoxybenzoyl)-6-iodo-indole,
2	commonly known as 6-iodopravadoline, or AM-630;
4	i. 1-[1-(N-methyl-2-piperidinyl)methyl]-3-(2-iodo-5-nitrobenzoyl) indole,
5	commonly known as AM–1241;
6	$j. \qquad 1-[1-(N-methyl-2-piperidinyl)methyl]-3-(2-iodobenzoyl)indole,$
7	commonly known as AM–2233;
8	7. Any compound structurally derived from 3-adamantoylindole by
9	substitution at the nitrogen atom of the indole ring with alkyl, haloalkyl, cyanoalkyl,
10	alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl) methyl,
11	2-(4-morpholinyl)ethyl, 1-(N-methyl-2-pyrrolidinyl)methyl,
12	$1-(N-methyl-3-morpholinyl) methyl, \ or \ (tetrahydropyran-4-yl) methyl \ group,$
13	whether or not further substituted in the indole ring to any extent, whether or not
14	substituted in the adamantyl ring to any extent. Substances specified under this
15	subdivision include:
16	$a. \qquad 1-[1-(N-methyl-2-piperidinyl)methyl]-3-(1-adamantoyl)indole,$
17	commonly known as AM-1248;
18	b. 1-pentyl-3-(1-adamantoyl)indole, commonly known as AB-001;
19	8. Any compound structurally derived from 3-(cyclopropoyl)indole by
20	substitution at the nitrogen atom of the indole ring with alkyl, haloalkyl, cyanoalkyl,
21	$alkenyl, \ cycloalkylmethyl, \ cycloalkylethyl, \ 1-(N-methyl-2-piperidinyl)methyl,$
22	2-(4-morpholinyl)ethyl, 1-(N-methyl-2-pyrrolidinyl)methyl,
23	$1-(N-methyl-3-morpholinyl) methyl, \ or \ (tetrahydropyran-4-yl) methyl \ group,$
24	whether or not further substituted in the indole ring to any extent, whether or not

1	substituted in the cyclopropyl ring to any extent. Substances specified under this
2	subdivision include:
3	a. 1-pentyl-3-(2,2,3,3-tetramethylcyclopropoyl)indole, commonly known as
4	UR-144;
5	$b. \ 1-(5-chloropentyl)-3-(2,2,3,3-tetramethylcyclopropoyl) indole, \ commonly \ begin{tabular}{ll} & & & & & & & & & & & & & & & & & & $
6	known as 5Cl–UR–144;
7	$c. 1-(5-fluor opentyl)-3-(2,2,3,3-tetramethyl cyclopropoyl) indole, \ commonly \\ $
8	known as XLR–11;
9	$d. \qquad 1-[2-(4-morpholinyl)ethyl]-3-(2,2,3,3-tetramethylcyclopropoyl) indole,$
10	commonly known as A–796,260;
11	e.
	1-[(tetrahydropyran-4-yl)methyl]-3-(2,2,3,3-tetramethylcyclopropoyl) indole,
12	commonly known as A-834,735;
14	9. Any compound structurally derived from
15	N-adamantyl-1H-indole-3-carboxamide by substitution at the nitrogen atom of
16	the indole ring with alkyl, haloalkyl, cyanoalkyl, alkenyl, cycloalkylmethyl,
17	cycloalkylethyl, 1-(N-methyl-2-piperidinyl) methyl, 2-(4-morpholinyl) ethyl,
18	$1-(N-methyl-2-pyrrolidinyl) methyl, \qquad 1-(N-methyl-3-morpholinyl) methyl, \qquad or$
19	(tetrahydropyran-4-yl)methyl group, whether or not further substituted in the
20	indole ring to any extent, whether or not substituted in the adamantyl ring to any
21	extent. Substances specified under this subdivision include:
22	a. N-(1-adamantyl)-1-pentyl-1H-indole-3-carboxamide, commonly known
23	as 2NE1;
$\frac{23}{24}$	

- 10 -

1	10.	Any	compound	structurally	derived	from
2	N-adamantyl-11	H-indazole	-3-carboxamide	e by substitution a	t either nitroge	n atom
3	of the indazole r	ing with a	lkyl, haloalkyl,	cyanoalkyl, alke	nyl, cycloalkyln	nethyl,
4	cycloalkylethyl,	1-(N-me	ethyl–2–piperidi	nyl)methyl, 2–	(4-morpholinyl)ethyl,
5	1-(N-methyl-2-	pyrrolidiny	l)methyl, 1-(N-methyl-3-mor	pholinyl)methy	l, or
6	(tetrahydropyrar	n–4–yl)metl	hyl group, whe	ther or not furth	er substituted	in the
7	indazole ring to a	any extent, [,]	whether or not s	substituted in the	adamantyl ring	to any
8	extent. Substan	ces specifie	d under this sub	odivision include:		
9	a. 1-pe	ntyl-N-(1-	adamantyl)–1H	-indazole-3-carb	ooxamide, com	imonly
10	known as AKB48	8;				
11	b. 1-(5-flue	oropentyl)-	N–(1–adamanty	yl)–1H–indazole–	3–carboxamide,	,
12	commonly known	n as 5F–AK	B48.			
13	11.	Any	compound	structurally	derived	from
				by substitution of	: .] :	n atom
14	N-naphthyl-1H-	-indazole-8	3-carboxamide I	by substitution at	t eitner nitrogei	ii atom
14 15				cyanoalkyl, alke	C	
	of the indazole r	ing with a	lkyl, haloalkyl,	•	nyl, cycloalkyln	nethyl,
15	of the indazole r cycloalkylethyl,	ring with a 1–(N–me	lkyl, haloalkyl, thyl-2-piperidi	cyanoalkyl, alke	nyl, cycloalkyln (4-morpholinyl	nethyl,)ethyl,
15 16	of the indazole r cycloalkylethyl, 1-(N-methyl-2-	ring with a 1–(N–me pyrrolidiny	lkyl, haloalkyl, ethyl–2–piperidi l)methyl, 1–(cyanoalkyl, alke nyl)methyl, 2-	nyl, cycloalkyln (4–morpholinyl pholinyl)methy	nethyl,)ethyl, l, or
15 16 17	of the indazole r cycloalkylethyl, 1-(N-methyl-2- (tetrahydropyrar	ing with a 1–(N–me pyrrolidiny n–4–yl)metl	lkyl, haloalkyl, ethyl-2-piperidi d)methyl, 1-(hyl group, whet	cyanoalkyl, alke nyl)methyl, 2– N–methyl–3–mor	nyl, cycloalkyln (4-morpholinyl pholinyl)methy er substituted	nethyl,)ethyl, l, or in the
15 16 17 18	of the indazole r cycloalkylethyl, 1-(N-methyl-2- (tetrahydropyrar	ing with a 1–(N–me pyrrolidiny n–4–yl)metl	lkyl, haloalkyl, ethyl-2-piperidi d)methyl, 1-(hyl group, whet	cyanoalkyl, alker nyl)methyl, 2– N–methyl–3–mor ther or not furth	nyl, cycloalkyln (4-morpholinyl pholinyl)methy er substituted	nethyl,)ethyl, l, or in the
15 16 17 18 19	of the indazole r cycloalkylethyl, 1–(N–methyl–2– (tetrahydropyrar indazole ring to a extent.	ing with a 1–(N–me pyrrolidiny n–4–yl)metl any extent,	lkyl, haloalkyl, ethyl–2–piperidi d)methyl, 1–(hyl group, whet whether or not	cyanoalkyl, alker nyl)methyl, 2– N–methyl–3–mor ther or not furth	nyl, cycloalkyln (4-morpholinyl pholinyl)methy er substituted e naphthyl ring	nethyl,)ethyl, l, or in the to any
15 16 17 18 19 20	of the indazole r cycloalkylethyl, 1–(N–methyl–2– (tetrahydropyrar indazole ring to a extent.	ing with a 1–(N–me pyrrolidiny n–4–yl)metl any extent,	lkyl, haloalkyl, ethyl–2–piperidi d)methyl, 1–(hyl group, whet whether or not	cyanoalkyl, alker nyl)methyl, 2– N–methyl–3–mor ther or not furth substituted in the	nyl, cycloalkyln (4-morpholinyl pholinyl)methy er substituted e naphthyl ring	nethyl,)ethyl, l, or in the to any
15 16 17 18 19 20 21	of the indazole r cycloalkylethyl, 1-(N-methyl-2- (tetrahydropyrar indazole ring to a extent. 12. [1,1'-bi	ing with a 1–(N–me pyrrolidiny n–4–yl)metl any extent,	lkyl, haloalkyl, ethyl–2–piperidi d)methyl, 1–(hyl group, whet whether or not	cyanoalkyl, alker nyl)methyl, 2– N–methyl–3–mor ther or not furth substituted in the	nyl, cycloalkyln (4-morpholinyl pholinyl)methy er substituted e naphthyl ring	nethyl,)ethyl, l, or in the to any

- 11 -

2013 – 2014 Legislature – 12 –

1	6a,7,8,9,10,10a-octahydrophenanthridin-1-yl] acetate, commonly known as CP
2	50,556-1;
3	14.
4	(6aR, 10aR) - 9 - (hydroxymethyl) - 6, 6 - dimethyl - 3 - (2 - methyloctan - 2 - yl) - 6a, 7, 10, 10, 10, 10, 10, 10, 10, 10, 10, 10
5	0a-tetrahydrobenzo[c]chromen-1-ol, commonly known as HU-210;
6	15.
7	(6aS, 10aS) - 9 - (hydroxymethyl) - 6, 6 - dimethyl - 3 - (2 - methyloctan - 2 - yl) - 6a, 7, 10, 10 - 6a, 10, 10, 10, 10, 10, 10, 10, 10, 10, 10
8	a-tetrahydrobenzo[c]chromen-1-ol, commonly known as HU-211;
9	16.
10	3-hydroxy-2-[(1R,6R)-3-methyl-6-(1-methylethenyl)-2-cyclohexen-1-yl]-5-pethylethenyl]-5-pethylethenyl]
11	ntyl-2,5-cyclohexadiene-1,4-dione, commonly known as HU-331;
12	17.
13	((6aR,10aR)-6,6-dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo)
14	[c]chromen-9-yl)methanol, commonly known as JWH-051;
15	$18. \qquad (6aR, 10aR) - 3 - (1, 1 - Dimethylbutyl) - 6a, 7, 10, 10a - tetrahydro$
16	-6,6,9-trimethyl-6H-dibenzo[b,d]pyran, commonly known as JWH-133;
17	19.
18	(6aR, 10aR) - 1 - methoxy - 6, 6, 9 - trimethyl - 3 - [(2R) - 1, 1, 2 - trimethyl butyl] - 6a, 7, 10, 10, 10, 10, 10, 10, 10, 10, 10, 10
19	0a-tetrahydrobenzo[c]chromene, commonly known as JWH-359;
20	$20. \qquad Napthalen-1-yl-(4-pentyloxynapthalen-1-yl) methanone, \ \ commonly \\$
21	known as CB-13;
22	21. N-cyclopropyl-11-(3-hydroxy-5-pentylphenoxy)-undecamide,
23	commonly known as CB-25;
24	$22. \ N-cyclopropyl-11-(2-hexyl-5-hydroxyphenoxy)-undecamide, \ commonly$
25	known as CB-52;

1	23.
2	N-(benzo[1,3]dioxol-5-ylmethyl)-7-methoxy-2-oxo-8-pentyloxy-1,2-dihydroquidle and a straight of the straight
3	noline–3–carboxamide, commonly known as JTE–907;
4	24.
5	N-[3-(2-methoxyethyl)-4, 5-dimethyl-1, 3-thiazol-2-ylidene]-2, 2, 3, 3-tetramethylow and a straight of the s
6	lcyclopropane-1-carboxamide, commonly known as A-836,339;
7	25.
8	$Anthracen-9-yl\{2-methyl-1-[2-(morpholin-4-yl)ethyl]-1H-indol-3-yl\}methano(2-methyl-1-[2-(morpholin-4-yl)ethyl]-1H-indol-3-yl\}methano(2-methyl-1-[2-(morpholin-4-yl)ethyl]-1H-indol-3-yl\}methano(2-methyl-1-[2-(morpholin-4-yl)ethyl]-1H-indol-3-yl\}methano(2-methyl-1-[2-(morpholin-4-yl)ethyl]-1H-indol-3-yl}methano(2-yl)ethyl]$
9	ne, commonly known as WIN 56,098;
10	26. 6-methyl-2-[(4-methylphenyl)amino]-4H-3,1-benzoxazin-4-one,
11	commonly known as URB-754;
12	27. [3-(3-carbamoylphenyl)phenyl] N-cyclohexylcarbamate, commonly
13	known as URB-597;
14	28.
15	(-)-(R)-3-(2-Hydroxymethylindanyl-4-oxy) phenyl-4, 4, 4-trifluorobutyl-1-sulfon (R)-3-(2-Hydroxymethylindanyl-4-oxy) phenyl-4, 4-trifluorobutyl-4-(R)-3-
16	ate, commonly known as BAY 38–7271.
17	29. Any compound structurally derived from 1H-indole-3-carboxylic acid
18	quinolinyl ester by substitution at the nitrogen atom of the indole ring by alkyl,
19	haloalkyl, cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,
20	1-(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl,
21	$1-(N-methyl-2-pyrrolidinyl) methyl, \qquad 1-(N-methyl-3-morpholinyl) methyl, \qquad or$
22	(tetrahydropyran-4-yl)methyl group, whether or not further substituted in the
23	indole ring to any extent, whether or not substituted in the quinoline ring to any
24	extent. Substances specified under this subdivision include:

- 13 -

ASSEMBLY BILL 406

1	a. 1-pentyl-1H-indole-3-carboxylic acid 8-quinolinyl ester, commonly known
2	as PB-22;
3	b. 1-(5-fluoropentyl)-1H-indole-3-carboxylic acid 8-quinolinyl ester,
4	commonly known as 5F-PB-22;
5	c. 1-(cyclohexylmethyl)-1H-indole-3-carboxylic acid 8-quinolinyl ester,
6	commonly known as BB-22.
7	30. Any compound structurally derived from
8	N-naphthyl-1H-indole-3-carboxamide by substitution at the nitrogen atom of the
9	indole ring with alkyl, haloalkyl, cyanoalkyl, alkenyl, cycloalkylmethyl,
10	cycloalkylethyl, 1-(N-methyl-2-piperidinyl) methyl, 2-(4-morpholinyl) ethyl,
11	$1-(N-methyl-2-pyrrolidinyl) methyl, \qquad 1-(N-methyl-3-morpholinyl) methyl, \qquad or$
12	(tetrahydropyran-4-yl)methyl group, whether or not further substituted in the
13	indole ring to any extent, whether or not substituted in the naphthyl ring to any
14	extent. Substances specified under this subdivision include:
15	a. 1-pentyl-N-(1-naphthyl)-1H-indole-3-carboxamide, commonly known as
16	NNEI or MN-24;
17	$b. \ 1-(5-fluor opentyl)-N-(1-naphthyl)-1H-indole-3-carboxamide, \ commonly here a common set of the common set of$
18	known as 5F–NNEI or 5F–MN–24.
19	31. Any compound structurally derived from 3-(pyridinoyl)indole by
20	substitution at the nitrogen atom of the indole ring by alkyl, haloalkyl, cyanoalkyl,
21	$alkenyl, \ cycloalkylmethyl, \ cycloalkylethyl, \ 1-(N-methyl-2-piperidinyl)methyl,$
22	2-(4-morpholinyl)ethyl, 1-(N-methyl-2-pyrrolidinyl)methyl,
23	$1-(N-methyl-3-morpholinyl) methyl, \ or \ (tetrahydropyran-4-yl) methyl \ group,$
24	whether or not further substituted in the indole ring to any extent, whether or not

- 14 -

ASSEMBLY BILL 406

1 substituted in the pyridine ring to any extent. Substances specified under this $\mathbf{2}$ subdivision include: 3 a. 1-pentyl-3-(3-pyridinoyl)indole; 4 b. 1-(5-fluoropentyl)-3-(3-pyridinoyl)indole. 5**SECTION 7.** 961.14 (4) (te), (th), (tL), (tp), (tr), (tu) and (ty) of the statutes are repealed. 6 7 **SECTION 8.** 961.14 (4) (uv) of the statutes is created to read: 961.14 **(4)** 8 2-(3-methoxyphenyl)-2-(ethylamino)cyclohexanone, (uv) 9 commonly known as methoxetamine. 10 **SECTION 9.** 961.14 (4) (wa) of the statutes is created to read: 11 961.14 (4) (wa) 4-iodo-2,5-dimethoxyamphetamine, commonly known as 12DOI. 13 **SECTION 10.** 961.14 (4) (wb) of the statutes is created to read: 14961.14 (4) (wb) 4-chloro-2,5-dimethoxyamphetamine, commonly known as DOC. 1516 **SECTION 11.** 961.14 (4) (wk) of the statutes is created to read: 17961.14 (4) (wk) 2,5-dimethoxy-4-ethylphenethylamine, commonly known as 2C-E. 18 19 **SECTION 12.** 961.14 (4) (wL) of the statutes is created to read: 20 961.14 (4) (wL) 2,5-dimethoxy-4-methylphenethylamine, commonly known 21as 2C–D. 22**SECTION 13.** 961.14 (4) (wm) of the statutes is created to read: 23961.14 (4) (wm) 2.5-dimethoxy-4-chlorophenethylamine, commonly known 24as 2C–C. **SECTION 14.** 961.14 (4) (wn) of the statutes is created to read: 25

- 15 -

ASSEMBLY BILL 406

1	961.14(4)(wn) 2,5-dimethoxy-4-ethylthiophenethylamine, commonly known
2	as 2C-T-2.
3	SECTION 15. 961.14 (4) (wo) of the statutes is created to read:
4	961.14 (4) (wo) 2,5-dimethoxy-4-isopropylthiophenethylamine, commonly
5	known as 2C–T–4.
6	SECTION 16. 961.14 (4) (wp) of the statutes is created to read:
7	961.14 (4) (wp) 2,5-dimethoxyphenethylamine, commonly known as $2C$ -H.
8	SECTION 17. 961.14 (4) (wq) of the statutes is created to read:
9	961.14 (4) (wq) 2,5-dimethoxy-4-nitrophenethylamine, commonly known as
10	2C-N.
11	SECTION 18. 961.14 (4) (wr) of the statutes is created to read:
12	961.14 (4) (wr) $2,5$ -dimethoxy-4-(n)-propylphenethylamine, commonly
13	known as 2C–P.
14	SECTION 19. 961.14 (4) (ws) of the statutes is created to read:
14 15	SECTION 19. 961.14 (4) (ws) of the statutes is created to read: 961.14 (4) (ws) Any compound structurally derived from
15	961.14 (4) (ws) Any compound structurally derived from
15 16	961.14 (4) (ws) Any compound structurally derived from N-benzyl-2-(2,5-dimethoxyphenyl)ethanamine by substitution at the nitrogen
15 16 17	961.14 (4) (ws) Any compound structurally derived from N-benzyl-2-(2,5-dimethoxyphenyl)ethanamine by substitution at the nitrogen atom, or on either ring, with alkyl, alkoxy, alkylenedioxy, haloalkyl, hydroxyl, halide
15 16 17 18	961.14 (4) (ws) Any compound structurally derived from N-benzyl-2-(2,5-dimethoxyphenyl)ethanamine by substitution at the nitrogen atom, or on either ring, with alkyl, alkoxy, alkylenedioxy, haloalkyl, hydroxyl, halide or nitro substituents, or by any combination of these modifications. Substances
15 16 17 18 19	961.14 (4) (ws) Any compound structurally derived from N-benzyl-2-(2,5-dimethoxyphenyl)ethanamine by substitution at the nitrogen atom, or on either ring, with alkyl, alkoxy, alkylenedioxy, haloalkyl, hydroxyl, halide or nitro substituents, or by any combination of these modifications. Substances specified under this paragraph include:
15 16 17 18 19	961.14 (4) (ws) Any compound structurally derived from N-benzyl-2-(2,5-dimethoxyphenyl)ethanamine by substitution at the nitrogen atom, or on either ring, with alkyl, alkoxy, alkylenedioxy, haloalkyl, hydroxyl, halide or nitro substituents, or by any combination of these modifications. Substances specified under this paragraph include: 1.
15 16 17 18 19 20	961.14 (4) (ws) Any compound structurally derived from N-benzyl-2-(2,5-dimethoxyphenyl)ethanamine by substitution at the nitrogen atom, or on either ring, with alkyl, alkoxy, alkylenedioxy, haloalkyl, hydroxyl, halide or nitro substituents, or by any combination of these modifications. Substances specified under this paragraph include: 1. 2-(4-iodo-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine,
15 16 17 18 19 20 22	961.14 (4) (ws) Any compound structurally derived from N-benzyl-2-(2,5-dimethoxyphenyl)ethanamine by substitution at the nitrogen atom, or on either ring, with alkyl, alkoxy, alkylenedioxy, haloalkyl, hydroxyl, halide or nitro substituents, or by any combination of these modifications. Substances specified under this paragraph include: 1. 2-(4-iodo-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine, commonly known as 25I-NBOMe.

- 16 -

1	3.
	2-(4-bromo-2, 5-dimethoxy phenyl) - N-[(2-methoxy phenyl) methyl] ethanamine,
2	commonly known as 25B–NBOMe.
4	$4. \qquad 2-(4-ethyl-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl) ethanamine,$
5	commonly known as 25E–NBOMe.
6	SECTION 20. 961.14 (4) (wv) of the statutes is created to read:
7	961.14 (4) (wv) N,N-diallyl-5-methoxytryptamine, commonly known as
8	5-MeO-DALT.
9	SECTION 21. 961.14 (4) (ww) of the statutes is created to read:
10	961.14 (4) (ww) 5-(2-aminopropyl)benzofuran, commonly known as 5-APB.
11	SECTION 22. 961.14 (4) (wx) of the statutes is created to read:
12	961.14 (4) (wx) 6-(2-aminopropyl)benzofuran, commonly known as 6-APB.
13	SECTION 23. 961.14 (4) (wy) of the statutes is created to read:
14	961.14 (4) (wy) 5-(2-aminopropyl)-2,3-dihydrobenzofuran, commonly known
15	as 5–APDB.
16	SECTION 24. 961.14 (4) (wz) of the statutes is created to read:
17	961.14 (4) (wz) 6-(2-aminopropyl)-2,3-dihydrobenzofuran, commonly known
18	as 6-APDB.
19	SECTION 25. 961.14 (4) (xa) of the statutes is created to read:
20	961.14 (4) (xa) 5-iodo-2-aminoindane, commonly known as 5-IAI.
21	SECTION 26. 961.14 (4) (xb) of the statutes is created to read:
22	961.14 (4) (xb) 4-methoxymethamphetamine, commonly known as PMMA.
23	SECTION 27. 961.14 (7) (intro.) of the statutes is amended to read:
24	961.14 (7) STIMULANTS. (intro.) Any material, compound, mixture or
25	preparation which contains any quantity of any of the following substances having

- 17 -

a stimulant effect on the central nervous system, including any of their precursors,
 analogs, salts, isomers and salts of isomers that are theoretically possible within the
 specific chemical designation:

- 18 -

4 **SECTION 28.** 961.14 (7) (L) of the statutes is repealed and recreated to read:

5 961.14 (7) (L) Substituted cathinones. Any compound, except bupropion or compounds scheduled elsewhere in this chapter, that is structurally derived from 6 7 2-amino-propan-1-one by substitution at the 1-position with either phenyl, 8 napthyl, or thiophene ring systems, whether or not the compound is further modified 9 in any of the following ways: by substitution in the ring system to any extent with 10 alkyl, alkoxy, alkylenedioxy, haloalkyl, hydroxyl, or halide substituents, whether or 11 not further substituted in the ring system by one or more other univalent 12substituents: by substitution at the 3-position with an acyclic alkyl substituent; by 13 substitution at the 2-amino nitrogen atom with alkyl, dialkyl, benzyl, or 14methoxybenzyl groups; by inclusion of the 2-amino nitrogen atom in a cyclic 15structure; or by any combination of these modifications. Substances specified under this subdivision include: 16

17 1. Methcathinone.

18 2. Methylenedioxypyrovalerone, commonly known as MDPV.

19 3. 4-methylmethcathinone, commonly known as mephedrone or 4-MMC.

20 4. 4-methylethcathinone, commonly known as 4-MEC.

21 5. 4-methoxy-alpha-pyrrolidinopropiophenone, commonly known as MOPPP.

- 6. 3,4-methylenedioxy-alpha-pyrrolidinopropiophenone, commonly knownas MDPPP.
- 24

7. Alpha-pyrrolidinovalerophenone, commonly known as alpha-PVP.

25 8. 2-fluoromethcathinone, commonly known as 2-FMC.

ASSEMBLY BILL 406

1	9. 3-fluoromethcathinone, commonly known as 3-FMC.
2	10. 4-fluoromethcathinone, commonly known as 4-FMC or flephedrone.
3	11. 3,4-methylenedioxymethcathinone, commonly known as methylone or
4	bk-MDMA.
5	12. Naphthylpyrovalerone, commonly known as naphyrone.
6	13. 4-methyl-alpha-pyrrolidinobutiophenone, commonly known as MPBP.
7	14. 4-methoxymethcathinone, commonly known as methedrone or bk-PMMA.
8	15. Ethcathinone.
9	16. 3,4-methylenedioxyethcathinone, commonly known as ethylone or
10	bk-MDEA.
11	17. beta-Keto-N-methylbenzodioxolylbutanamine, commonly known as
12	butylone or bk-MBDB.
13	18. N,N-dimethylcathinone, commonly known as metamfepramone.
14	19. Alpha-pyrrolidinopropiophenone, commonly known as alpha-PPP.
15	20. 3-methoxymethcathinone, commonly known as 3-MMC.
16	21. 4-ethylmethcathinone, commonly known as 4-EMC.
17	22. 3,4-dimethylmethcathinone, commonly known as 3,4-DMMC.
18	23. beta-Keto-N-methylbenzodioxolylpentanamine, commonly known as
19	pentylone or bk–MBDP.
20	24. beta-Keto-ethylbenzodioxolylbutanamine, commonly known as eutylone
21	or bk-EBDB.
22	25. 4-bromomethcathinone, commonly known as 4-BMC.
23	26. Alpha-methylamino-butyrophenone, commonly known as buphedrone or
24	MABP.

- 19 -

ASSEMBLY BILL 406

1	27. 3,4-methylenedioxy-alpha-pyrrolidinobutiophenone, commonly known
2	as MDPBP.
3	28. 4-methyl-alpha-pyrrolidinohexiophenone, commonly known as MPHP.
4	29. N,N-dimethyl-3,4-methylenedioxycathinone.
5	30. N,N-diethyl-3,4-methylenedioxycathinone.
6	31. Alpha-methylamino-valerophenone, commonly known as pentedrone.
7	SECTION 29. 961.14 (7) (m) and (n) of the statutes are repealed.
8	SECTION 30. 961.14 (7) (mk) of the statutes is created to read:
9	961.14 (7) (mk) Mitragynine.
10	SECTION 31. 961.14 (7) (mL) of the statutes is created to read:
11	961.14 (7) (mL) 7-hydroxymitragynine.
12	SECTION 32. 961.14 (7) (mm) of the statutes is created to read:
13	961.14 (7) (mm) 5,6-methylenedioxy-2-aminoindane, commonly known as
14	MDAI.
15	SECTION 33. 961.14 (7) (mn) of the statutes is created to read:
16	961.14 (7) (mn) Benzothiophenylcyclohexylpiperidine, commonly known as
17	BTCP.
18	SECTION 34. 961.16 (3) (tb) of the statutes is created to read:
19	961.16 (3) (tb) Oripavine.
20	SECTION 35. 961.16 (3) (zt) of the statutes is created to read:
21	961.16 (3) (zt) Tapentadol.
22	SECTION 36. 961.16 (8) (b) of the statutes is created to read:
23	961.16 (8) (b) An immediate precursor to fentanyl, including
24	4-anilino-N-phenethyl-4-piperidine, commonly known as ANPP.
25	SECTION 37. 961.18 (7) (am) of the statutes is created to read:

- 20 -

ASSEMBLY BILL 406

1	961.18 (7) (am) 19-Nor-4,9(10)-androstadienedione;
2	SECTION 38. 961.18 (7) (az) of the statutes is created to read:
3	961.18 (7) (az) Boldione;
4	SECTION 39. 961.18 (7) (em) of the statutes is created to read:
5	961.18 (7) (em) Desoxymethyltestosterone;
6	SECTION 40. 961.20 (2) (ax) of the statutes is created to read:
7	961.20 (2) (ax) Carisoprodol;
8	SECTION 41. 961.20 (2) (q) of the statutes is created to read:
9	961.20 (2) (q) Zopiclone.
10	SECTION 42. 961.20 (4) (d) of the statutes is created to read:
11	961.20 (4) (d) Lorcaserin, including any of its isomers and salts of isomers.
12	SECTION 43. 961.22 (4) of the statutes is created to read:
13	961.22 (4) EZOGABINE. Ezogabine or any of its salts, isomers, or salts of isomers.
14	SECTION 44. 961.22 (5) of the statutes is created to read:
15	961.22 (5) PREGABALIN. Pregabalin or any of its salts, isomers, or salts of
16	isomers.
17	SECTION 45. 961.41 (1) (e) (intro.) of the statutes is amended to read:
18	961.41 (1) (e) Phencyclidine, amphetamine, methamphetamine,
19	methcathinone, <u>cathinone</u> , <u>methylenedioxypyrovalerone</u> , and
20	4-methylmethcathinone, N-benzylpiperazine, and a substance specified in s. 961.14
21	(7) (L). (intro.) If the person violates this subsection with respect to phencyclidine,
22	amphetamine, methamphetamine, methcathinone, <u>cathinone</u> ,
23	methylenedioxypyrovalerone, or 4-methylmethcathinone, $N-benzylpiperazine, a$
24	substance specified in s. 961.14 (7) (L), or a controlled substance analog of
25	phencyclidine, amphetamine, methamphetamine, methcathinone, <u>cathinone,</u>

- 21 -

ASSEMBLY BILL 406

1	methylenedioxypyrovalerone, or 4-methylmethcathinone, <u>N-benzylpiperazine, or a</u>
2	substance specified in s. 961.14 (7) (L), and the amount manufactured, distributed,
3	or delivered is:
4	SECTION 46. 961.41 (1) (em) of the statutes is created to read:
5	961.41 (1) (em) Synthetic cannabinoids. If a person violates this subsection
6	with respect to a controlled substance specified in s. 961.14 (4) (tb), or a controlled
7	substance analog of a controlled substance specified in s. 961.14 (4) (tb), and the
8	amount manufactured, distributed, or delivered is:
9	1. Two hundred grams or less, the person is guilty of a Class I felony.
10	2. More than 200 grams but not more than 1,000 grams, the person is guilty
11	of a Class H felony.
12	3. More than 1,000 grams but not more than 2,500 grams, the person is guilty
13	of a Class G felony.
14	4. More than 2,500 grams but not more than 10,000 grams, the person is guilty
15	of a Class F felony.
16	5. More than 10,000 grams, the person is guilty of a Class E felony.
17	SECTION 47. 961.41 (1) (hm) (intro.) of the statutes is amended to read:
18	961.41 (1) (hm) Certain other schedule I controlled substances and ketamine.
19	(intro.) If the person violates this subsection with respect to gamma-hydroxybutyric
20	acid, gamma-butyrolactone, 1,4-butanediol,
	3,4-methylenedioxymethamphetamine,
22	4-bromo-2, 5-dimethoxy-beta-phenylethylamine, 4-methylthioamphetamine,
23	ketamine, <u>a substance specified in s. 961.14 (4) (a) to (h), (m) to (q), (sm), or (u) to (xb)</u> ,
24	or a controlled substance analog of gamma-hydroxybutyric acid,
25	gamma-butyrolactone, 1,4-butanediol, 3,4-methylenedioxymethamphetamine,

- 22 -

ASSEMBLY BILL 406

1	4-bromo-2,5-dimethoxy-beta-phenylethylamine, or 4-methylthioamphetamine,
2	ketamine, or a substance specified in s. 961.14 (4) (a) to (h), (m) to (q), (sm), or (u) to
3	(xb), and the amount manufactured, distributed, or delivered is:
4	SECTION 48. 961.41 (1m) (e) (intro.) of the statutes is amended to read:
5	961.41 (1m) (e) Phencyclidine, amphetamine, methamphetamine,
6	methcathinone, <u>cathinone</u> , <u>methylenedioxypyrovalerone</u> , and
7	4-methylmethcathinone, N-benzylpiperazine, and a substance specified in s. 961.14
8	(7) (L). (intro.) If a person violates this subsection with respect to phencyclidine,
9	amphetamine, methamphetamine, methcathinone, <u>cathinone</u> ,
10	methylenedioxypyrovalerone, or 4-methylmethcathinone, N-benzylpiperazine, a
11	substance specified in s. 961.14 (7) (L), or a controlled substance analog of
12	phencyclidine, amphetamine, methamphetamine, methcathinone, <u>cathinone</u> ,
13	methylenedioxypyrovalerone, or 4-methylmethcathinone, <u>N-benzylpiperazine, or a</u>
14	substance specified in s. 961.14 (7) (L), and the amount possessed, with intent to
15	manufacture, distribute, or deliver, is:
16	SECTION 49. 961.41 $(1m)$ (em) of the statutes is created to read:
17	961.41 (1m) (em) Synthetic cannabinoids. If a person violates this subsection
18	with respect to a controlled substance specified in s. 961.14 (4) (tb), or a controlled
19	substance analog of a controlled substance specified in s. 961.14 (4) (tb), and the
20	amount possessed, with intent to manufacture, distribute, or deliver, is:
21	1. Two hundred grams or less, the person is guilty of a Class I felony.
22	2. More than 200 grams but not more than 1,000 grams, the person is guilty of
23	a Class H felony.
24	3. More than 1,000 grams but not more than 2,500 grams, the person is guilty
25	of a Class G felony.

ASSEMBLY BILL 406

 $\mathbf{24}$

1	4. More than 2,500 grams but not more than 10,000 grams, the person is guilty
2	of a Class F felony.
3	5. More than 10,000 grams, the person is guilty of a Class E felony.
4	SECTION 50. 961.41 (1m) (hm) (intro.) of the statutes is amended to read:
5	961.41 (1m) (hm) Certain other schedule I controlled substances and ketamine.
6	(intro.) If the person violates this subsection with respect to gamma-hydroxybutyric
7	acid, gamma-butyrolactone, 1,4-butanediol,
	3,4-methylenedioxymethamphetamine,
9	eq:2.5-dimethoxy-beta-phenylethylamine, 4-methylthioamphetamine, 4-methylthioamphetamin
10	ketamine, <u>a substance specified in s. 961.14 (4) (a) to (h), (m) to (q), (sm), or (u) to (xb)</u> ,
11	or a controlled substance analog of gamma-hydroxybutyric acid,
12	gamma-butyrolactone, 1,4-butanediol, 3,4-methylenedioxymethamphetamine,
13	4-bromo- $2,5$ -dimethoxy-beta-phenylethylamine, or 4 -methylthioamphetamine,
14	ketamine, or a substance specified in s. 961.14 (4) (a) to (h), (m) to (q), (sm), or (u) to
15	(\underline{xb}) is subject to the following penalties if the amount possessed, with intent to
16	manufacture, distribute, or deliver is:
17	SECTION 51. 961.41 (1r) of the statutes is amended to read:
18	961.41 (1r) DETERMINING WEIGHT OF SUBSTANCE. In determining amounts under
19	s. 961.49 (2) (b), 1999 stats., and subs. (1) and (1m), an amount includes the weight $% \left(1,1,2,2,3,3,3,3,3,3,3,3,3,3,3,3,3,3,3,3,$
20	of cocaine, cocaine base, heroin, phencyclidine, lysergic acid diethylamide, psilocin,
21	psilocybin, amphetamine, methamphetamine, methcathinone or
22	tetrahydrocannabinols, synthetic cannabinoids or substituted cathinones, or any
23	controlled substance analog of any of these substances together with any compound,

25 controlled substance or controlled substance analog. In addition, in determining

mixture, diluent, plant material or other substance mixed or combined with the

- 24 -

ASSEMBLY BILL 406

amounts under subs. (1) (h) and (1m) (h), the amount of tetrahydrocannabinols
means anything included under s. 961.14 (4) (t) and includes the weight of any
marijuana.

SECTION 52. 961.41 (3g) (d) of the statutes is amended to read:

 $\mathbf{5}$ 961.41 (3g) (d) Certain hallucinogenic and stimulant drugs. If a person 6 possesses or attempts to possess lysergic acid diethylamide, phencyclidine, 7 amphetamine, 3,4-methylenedioxymethamphetamine, methcathinone, cathinone, 8 methylenedioxypyrovalerone, 4-methylmethcathinone, N-benzylpiperazine, a 9 substance specified in s. 961.14 (4) (a) to (h), (m) to (q), (sm), (u) to (xb), or (7) (L), 10 psilocin, or psilocybin, or a controlled substance analog of lysergic acid diethylamide, 11 phencyclidine, 3,4-methylenedioxymethamphetamine, amphetamine, 12methcathinone, <u>cathinone</u>, <u>methylenedioxypyrovalerone</u>, <u>4-methylmethcathinone</u>, 13 N-benzylpiperazine, a substance specified in s. 961.14 (4) (a) to (h), (m) to (q), (sm), 14(u) to (xb), or (7) (L), psilocin, or psilocybin, the person may be fined not more than 15\$5,000 or imprisoned for not more than one year in the county jail or both upon a first conviction and is guilty of a Class I felony for a 2nd or subsequent offense. For 16 17purposes of this paragraph, an offense is considered a 2nd or subsequent offense if, 18 prior to the offender's conviction of the offense, the offender has at any time been 19 convicted of any felony or misdemeanor under this chapter or under any statute of 20 the United States or of any state relating to controlled substances, controlled 21substance analogs, narcotic drugs, marijuana, or depressant, stimulant, or 22hallucinogenic drugs.

23

4

SECTION 53. 961.41 (3g) (em) of the statutes is amended to read:

961.41 (3g) (em) Synthetic cannabinoids. If a person possesses or attempts to
possess a controlled substance specified in s. 961.14 (4) (tb) to (ty), or a controlled

ASSEMBLY BILL 406

1 substance analog of a controlled substance specified in s. 961.14 (4) (tb) to (ty), the $\mathbf{2}$ person may be fined not more than \$1,000 or imprisoned for not more than 6 months 3 or both upon a first conviction and is guilty of a Class I felony for a 2nd or subsequent offense. For purposes of this paragraph, an offense is considered a 2nd or subsequent 4 $\mathbf{5}$ offense if, prior to the offender's conviction of the offense, the offender has at any time 6 been convicted of any felony or misdemeanor under this chapter or under any statute 7 of the United States or of any state relating to controlled substances, controlled 8 substance analogs, narcotic drugs, marijuana, or depressant, stimulant, or 9 hallucinogenic drugs.

10

(END)